Language Use in Deaf Children with Early-signing versus Late-signing Deaf Parents

Contains fulltext : 246462.pdf (Publisher’s version ) (Open Access)Previous research has shown that spatial language is sensitive to the effects of delayed language exposure. Locative encodings of late-signing deaf adults varied from those of early-signing deaf adults in the preferred types of linguistic forms. In the current study, we investigated whether such differences would be found in spatial language use of deaf children with deaf parents who are either early or late signers of Turkish Sign Language (TİD). We analyzed locative encodings elicited from these two groups of deaf children for the use of different linguistic forms and the types of classifier handshapes. Our findings revealed differences between these two groups of deaf children in their preferred types of linguistic forms, which showed parallels to differences between late versus early deaf adult signers as reported by earlier studies. Deaf children in the current study, however, were similar to each other in the type of classifier handshapes that they used in their classifier constructions. Our findings have implications for expanding current knowledge on to what extent variation in language input (i.e., from early vs. late deaf signers) is reflected in children’s productions as well as the role of linguistic input on language development in general.14 p

Paracervical block with 1% lidocaine for pain control during intrauterine device insertion: a prospective, single-blinded, controlled study

In this prospective controlled study we aimed to investigate efficacy of paracervical block with 1% Lidocaine for pain control and demographic variables which may affect pain perception during intrauterine device insertion in Turkish women. Data from 95 women assigned to paracervical block (n=34), placebo (n=30) and no treatment (n=31) arms and asked to grade the pain level they  felt during tenaculum placement, intrauterine device insertion and 5 minutes after the procedure using a visual pain scale. Demographic variables were also recorded. Pain scores were found to be lower in paracervical block group when compared to other 2 groups during tenaculum placement (p=0.00), intrauterine device insertion (p=0.00) and 5 minutes after the procedure (p=0.00). Level of pain was unrelated to mode of previous deliveries and current breastfeeding. Paracervical block is an easy, safe and effective way of pain control during intrauterine device insertion. Lack of vaginal birth history is not a reason to draw back from intrauterine device use

Cost-effectiveness of sorafenib for treatment of radioactive iodine (rai)-refractory locally advanced/metastatic differentiated thyroid cancer (dtc) in Turkey

WOS: 000354498503198OBJECTIVES: Sorafenib is the first product approved for treatment of RAI refractory locally advanced/metastatic DTC patients. This study was conducted in order to analyze cost-effectiveness of sorafenib for treatment of patients with RAI refractory locally advanced/metastatic DTC in Turkey. METHODS: A cohort partition model assigning patients to one of three health states according to the proportion of patients who are progression-free, progressed, or dead in each 28-days cycle was adapted to Turkish setting. The incremental cost-effectiveness ratios (ICER) were calculated per quality-adjusted life years (QALYs) and life-years (LYs) gained. Turkish payer’s perspective was taken and time-horizon was set as patient’s lifetime (maximum 30 years). Sorafenib was compared to the best supportive care (BSC) within the model since there are no agents for treatment of patients on this stage of the disease. Essential clinical inputs were derived from DECISION trial and local resource-utilization data were based on expert opinions through an expert panel. Sensitivity of the results was evaluated in terms of key inputs by deterministic oneway and probabilistic sensitivity analyses. All costs were calculated in Turkish Liras (TL) and converted to USD using TL/USD currency rate as 2.2 (mid-2014). RESULTS: Total cost of sorafenib-treated patients is 24,384 USD higher compared to BSC. Besides, sorafenib is associated with increments of 1.29 LYs and 0.80 QALYs compared to BSC. The ICER of sorafenib per LYs and QALYs gained compared to BSC were determined as 18,851 USD and 30,485 USD respectively. One-way sensitivity analysis demonstrated that results are not sensitive to the changes in model inputs and pharmacoeconomic analysis results were validated by probabilistic sensitivity analysis. CONCLUSIONS: Sorafenib is cost-effective for treatment of patients with RAI refractory locally advanced/metastatic DTC compared to BSC with an ICER value below the willingness-to-pay threshold (3-times GDP per capita ─ 32,346 USD) for Turkey